261 related articles for article (PubMed ID: 21882256)
21. Use of mutation profiles to refine the classification of endometrial carcinomas.
McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
[TBL] [Abstract][Full Text] [Related]
22. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract][Full Text] [Related]
23. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
24. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance.
Jarboe EA; Miron A; Carlson JW; Hirsch MS; Kindelberger D; Mutter GL; Crum CP; Nucci MR
Int J Gynecol Pathol; 2009 Jul; 28(4):308-15. PubMed ID: 19483636
[TBL] [Abstract][Full Text] [Related]
25. Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
O'Connor CM; Taylor SE; Miller KM; Hurst L; Haanen TJ; Suhan TK; Zawacki KP; Noto FK; Trako J; Mohan A; Sangodkar J; Zamarin D; DiFeo A; Narla G
Cancer Res; 2022 Feb; 82(4):721-733. PubMed ID: 34921012
[TBL] [Abstract][Full Text] [Related]
26. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
27. Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
Haines K; Huang GS
Cancer Res; 2019 Aug; 79(16):4009-4010. PubMed ID: 31416848
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
[TBL] [Abstract][Full Text] [Related]
29. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
Jia L; Liu Y; Yi X; Miron A; Crum CP; Kong B; Zheng W
Clin Cancer Res; 2008 Apr; 14(8):2263-9. PubMed ID: 18369088
[TBL] [Abstract][Full Text] [Related]
30. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.
Jeong AL; Han S; Lee S; Su Park J; Lu Y; Yu S; Li J; Chun KH; Mills GB; Yang Y
Sci Rep; 2016 Jun; 6():27391. PubMed ID: 27272709
[TBL] [Abstract][Full Text] [Related]
31. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
32. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
33. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
Pothuri B; Ramondetta L; Eifel P; Deavers MT; Wilton A; Alektiar K; Barakat R; Soslow RA
Gynecol Oncol; 2006 Dec; 103(3):948-51. PubMed ID: 16870239
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical loss of BRCA1 protein in uterine serous carcinoma.
Hecht JL; Konstantinopoulos PA; Awtrey CS; Soslow RA
Int J Gynecol Pathol; 2014 May; 33(3):282-7. PubMed ID: 24681740
[TBL] [Abstract][Full Text] [Related]
35. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
36. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
37. FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
Byron SA; Gartside MG; Wellens CL; Goodfellow PJ; Birrer MJ; Campbell IG; Pollock PM
Gynecol Oncol; 2010 Apr; 117(1):125-9. PubMed ID: 20106510
[TBL] [Abstract][Full Text] [Related]
38. Genomic aberrations in carcinomas of the uterine corpus.
Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
[TBL] [Abstract][Full Text] [Related]
39. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
40. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
